TransMedics reported second quarter 2026 revenue of $189.9 million, up 21% year-over-year, beating analyst expectations of $184.2 million. However, diluted earnings per share came in at $0.41, missing consensus estimates of $0.50, as a 49% increase in operating expenses pressured profitability. The company raised the low end of its full-year 2026 revenue guidance.
Key Highlights
- Second quarter revenue grew 21% year-over-year to $189.9 million, driven by increased utilization of the Organ Care System (OCS).
- Service revenue grew 29% to $78.8 million, outpacing the 16% growth in Product revenue which reached $111.2 million.
- Full-year 2026 revenue guidance was revised to a range of $737 million to $757 million, raising the low end from a previous range of $727 million to $757 million.
- Operating income declined to $23.7 million from $36.6 million a year ago, reflecting planned investments in R&D and infrastructure to support growth.